Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Articles|July 30, 2007
BREAKING NEWS: FDA Advisers Recommend Diabetes Drug Stay on Market
Author(s)Peggy Peck
Gaithersburg, Md. -- By a vote of 20 to three a group of FDA advisers found evidence that rosiglitazone (Avandia), the popular oral anti-diabetes drug, increases the risk of myocardial infarction. But the same advisers said the drug should stay on the market.
Advertisement
GAITHERSBURG, Md. July 30 -- By a vote of 20 to three a group of FDA advisers found evidence that rosiglitazone (Avandia), the popular oral anti-diabetes drug, increases the risk of myocardial infarction. But the same advisers said the drug should stay on the market.
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
Advertisement
Advertisement
Trending on Patient Care Online
1
Most Adolescents With Colorectal Cancer Diagnosed at Advanced Stage, Study Finds
2
Updated Freenome CRC Blood Test Detects 18.2% of Advanced Precancerous Lesions
3
Building Clinician Confidence to Prescribe HIV PrEP in Primary Care
4
PrEP Deserts: Why HIV Prevention Still Misses Those at Risk
5